Introduction
The recent introduction of targeted therapy has expanded the systemic treatment options for patients with advanced neuroendocrine tumors (NET). The mammalian target of rapamycin (mTOR) is a serine-threonine kinase that participates in the regulation of cell growth, proliferation, and apoptosis through modulation of the cell cycle [1] . mTOR mediates downstream signaling from a number of pathways, including VEGF, that are implicated in neuroendocrine tumor growth. A recent randomized study demonstrated improvement in progression-free survival (PFS) of patients with advanced pancreatic NET treated with the mTOR inhibitor everolimus [2] . In patients with carcinoid tumors, treatment with everolimus and octreotide was associated with a longer progression-free survival duration compared to octreotide alone when measured according to local investigator assessment [3] .
A key role for angiogenesis and VEGF pathway signaling in NET has been suggested by clinical observations that neuroendocrine tumors are vascular tumors. Additionally, preclinical studies have demonstrated that neuroendocrine tumors have increased expression of VEGF, VEGF receptor-2 (VEGFR-2), and other growth factor receptors including platelet-derived growth factor receptors (PDGFRs) a and b, and stem-cell factor receptor (c-kit) [4] [5] [6] [7] [8] . A recent randomized, placebo-controlled trial demonstrated improved progression-free survival of patients with advanced pancreatic NET treated with the tyrosine kinase inhibitor sunitinib [9] . Sorafenib, which has activity against VEGFR-2, PDGFR-B, and b-Raf, has also demonstrated evidence of activity in neuroendocrine tumors. In a phase II study that included 43 patients with pancreatic NETs and 50 patients with carcinoid tumor, responses were observed in 7 % of the carcinoid patients and 11 % of the patients with pancreatic NET [10] .
Because of possible synergistic effects of combining of an mTOR inhibitor with an inhibitor of the VEGF pathway, we performed a phase I study to evaluate the safety and feasibility of combining everolimus and sorafenib in patients with advanced NET. Cohorts of patients were treated with everolimus 10 mg daily and escalating doses of sorafenib beginning at a dose of 200 mg twice daily. Patients were followed for evidence of toxicity and preliminary evidence of efficacy. Treatment was continued until tumor progression, unacceptable toxicity, or withdrawal of consent.
Patients and methods

Patient population
All patients were required to be 18 years of age or older and have histologically documented, locally unresectable or metastatic carcinoid or pancreatic neuroendocrine tumors of low-or intermediate-grade histology. Patients with poorly differentiated or high-grade neuroendocrine carcinomas were not eligible. Treatment with prior chemotherapy was allowed, as was prior chemoembolization, cryotherapy, or radiofrequency ablation if measurable disease was not affected. Prior bevacizumab was permitted if last dose was greater than 6 weeks from initiation of protocol therapy. Patients were excluded if they had received prior treatment with everolimus or sorafenib. Mandated laboratory requirements included: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) B2.5 times the upper limit of normal (ULN) (B5 times ULN if liver metastasis was present), total bilirubin B1.5 times ULN, serum creatinine B1.5 times ULN, absolute neutrophil count (ANC) C1,500/mm 3 , and platelet count C100,000/mm 3 . All patients were required to have Eastern Cooperative Oncology Group (ECOG) performance status B1. Patients with a history of congestive heart failure, myocardial infarction, or unstable angina pectoris within 6 months preceding enrollment were excluded.
Patients on chronic steroids or immunosuppressive therapy or with active or suspected chronic infections, including a history of chronic hepatitis B, were excluded. All patients provided written informed consent for participation in the study, which was approved by the institutional review boards of participating institutions. The study was registered with clinicaltrials.gov (NCT00942682).
Treatment and dose escalation
Patients were treated with oral everolimus at a dose of 10 mg once daily in combination with oral sorafenib twice daily. Patients enrolled at dose level 1 received sorafenib 200 mg twice daily, and patients enrolled at dose level 2 received sorafenib 200 mg in the morning and 400 mg in the evening.
A minimum of 3 and a maximum of 6 patients were enrolled in sequential cohorts according to a standard phase I dose escalation design. Dose escalation to the next cohort proceeded in the absence of more than one of six patients experiencing a dose-limiting toxicity (DLT). DLT was defined as grade 3 or higher non-hematologic toxicity (excluding untreated hyperglycemia; hyperlipidemia; or nausea, vomiting, and diarrhea uncontrolled by aggressive supportive measures), or grade 3 or higher hematologic toxicity lasting C7 days. Isolated grade 3 laboratory abnormalities were to be deemed clinically significant by the treating investigator to be considered DLT. DLT was defined within the first cycle (28 days) of treatment. Once the MTD was established, treatment of 12 additional patients at the MTD was planned to further characterize safety and toxicity.
Dose adjustments in sorafenib and everolimus were made for hematologic toxicity. Both agents were held if patients developed an absolute neutrophil count \1,000/mm 3 or a platelet count \50,000/mm 3 . On recovery, treatment was resumed with dose reduction of everolimus to 5 mg daily (if receiving 10 mg daily) or to 5 mg every other day (if receiving 5 mg daily). For patients receiving sorafenib at a dose of 200 mg in the morning and 400 mg in the evening, sorafenib was reduced to 200 mg twice daily. Treatment with both drugs was also held for intolerable grade 2 or higher stomatitis, grade 2 or higher pneumonitis, or other non-hematologic toxicity that was grade 3 or higher (aside from hyperglycemia and hyperlipidemia, which were medically managed). Treatment was resumed with dose reduction pending resolution of non-hematologic toxicities to grade 1 or less. If non-hematologic toxicity did not recover within 3 weeks or if the patient experienced an unacceptable toxicity, study treatment was discontinued.
Treatment was continued until tumor progression, unacceptable toxicity, or withdrawal of consent. The study sponsors provided everolimus (Novartis) and sorafenib (Bayer).
Safety and response assessments
Patients were evaluated with a physical examination, serum chemistries, hematologic parameters, and for toxicity on days 1 and 15 of the first 28-day treatment cycle and on day 1 of subsequent treatment cycles. Toxicity was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Serum chromogranin and fasting lipid panel were obtained at baseline and after every two treatment cycles. Tumor response was evaluated at the end of every other 28-day treatment period using multi-phasic computed tomography (CT), or magnetic resonance imaging (MRI).
Results
Patient characteristics
Characteristics of 21 patients enrolled in the study are listed in Table 1 . The median age of the enrolled patients was 53 years, and 11 were males. Eighteen patients had carcinoid tumor, of which most were of small bowel origin, and three patients had pancreatic neuroendocrine tumor.
Dose escalation and dose-limiting toxicities
The dose escalation schema and associated DLTs are described in Table 2 . One patient treated at dose level 1 experienced protocol-defined DLT (grade 3 skin rash); the cohort was expanded to 6 patients with no further observed DLTs. In the absence of additional DLT at dose level 1, enrollment to dose level 2 was initiated. All 3 patients treated at dose level 2 experienced DLT (grade 3 thrombocytopenia requiring holding treatment for [14 days, grade 3 hand-foot skin reaction, and grade 3 skin rash/ allergic reaction). Sorafenib 200 mg twice daily in combination with everolimus 10 mg daily was established as the MTD. An additional 12 patients were treated at the MTD level to further characterize safety and toxicity.
Exposure to treatment and clinical toxicities All twenty-one enrolled patients received at least one dose of study treatment and were evaluable for toxicity. Patients received a median of four 28-day treatment cycles (range 0-26). Three patients discontinued treatment due to toxicity, including grade 3 pneumonitis (n = 1), grade 3 skin rash (n = 1), and grade 3 elevation in ALT/AST (n = 1) that resolved after discontinuation of study therapy. One patient treated at dose level 1 experienced fatal gastric perforation that occurred 37 days after following initiation of therapy and outside the DLT observation period. Disease progression was the most common reason for treatment discontinuation; of the 12 patients who discontinued therapy due to progression, six had documented radiologic progression by RECIST and six discontinued treatment due to clinical progression. Five patients discontinued treatment after withdrawing consent.
Suspected treatment-related adverse events across all treatment cycles are summarized in Table 3 . Most of the observed toxicities were mild in nature, most commonly fatigue, nausea, rash, diarrhea, or electrolyte abnormalities. Treatment-related grade 3-4 non-hematologic adverse events observed in more than one patient at dose level 1 included diarrhea (n = 3), hypophosphatemia (n = 3), hypocalcemia (n = 2), and rash (n = 2). Grade 3-4 elevation in ALT/AST, hand-foot skin reaction, hyperglycemia, hypertension, hypertriglyceridemia, hypokalemia, hyponatremia, and pneumonitis occurred in one patient each. Grade 3-4 hematologic toxicities experienced at dose level 1 included thrombocytopenia (n = 2), neutropenia (n = 1), and leucopenia (n = 1). Treatment-related grade 3-4 non-hematologic adverse events observed at dose level 2 included rash/ allergic reaction, anorexia, dehydration, hand-foot skin reaction, hypophosphatemia, and nausea. Grade 3-4 hematologic toxicities experienced by patients treated at dose level 2 included thrombocytopenia and lymphopenia.
Treatment efficacy
Patients were followed for radiographic response with cross-sectional imaging studies after every other cycle of treatment and for biochemical response with assessment of chromogranin A (CGA) levels after every cycle of treatment. Among 17 patients evaluable for radiographic response, one (6 %) experienced a partial response by RECIST as the best response to therapy, 13 (76 %) had stable disease, and 3 (18 %) had progressive disease. Including all enrolled patients, 13 (62 %) experienced some degree of tumor shrinkage during the course of treatment (Fig. 1) . The proportion of patients on study who were progression-free at 6 months was 79 %. Nineteen patients had elevated CGA levels at baseline. Of these patients, 5 (26 %) had a CGA level decrease of 50 % or greater from baseline.
Discussion
In this phase I study, we found that the combination of everolimus and sorafenib in patients with advanced NET was associated with toxicity that limited escalation to the anticipated full doses of both agents together. In our study, all patients receiving everolimus at a dose of 10 mg daily Grade 3 hand-foot skin reaction (n = 1)
Grade 3 skin rash/allergic reaction (n = 1) with more than 200 mg twice daily of sorafenib experienced DLT. Electrolyte abnormalities, including hypophosphatemia and hypocalcemia, were common across all grades. Hypophosphatemia was also noted as one of the more common grade 3-4 adverse events in patients with pancreatic NET treated with everolimus in the RADIANT 3 study [2] . Furthermore, hypophosphatemia has also been observed in patients with advanced renal cell carcinoma receiving sorafenib (16 % grade 3-4) [11] . Possible mechanisms underlying the hypophosphatemia associated with sorafenib include development of pancreatic exocrine dysfunction and vitamin D deficiency [12] . The frequency of hypophosphatemia that we observed may be related to additive effects of sorafenib and everolimus. In addition, patients with neuroendocrine tumors possibly may be more susceptible to electrolyte abnormalities due to their underlying disease and concurrent therapy with somatostatin analogs that also can be associated with pancreatic insufficiency.
In our study, the combination of sorafenib and everolimus was associated with a RECIST-defined partial response in one patient and some degree of tumor regression in 13/21 (62 %) of patients. Due to possible synergistic effects, combining everolimus with an inhibitor of the VEGF pathway offers a promising treatment approach for patients with NET. However, our results suggest that combining everolimus with a tyrosine kinase inhibitor of the VEGF pathway is associated with treatment-related toxicity that requires dose modification of either or both agents. Attenuated dosing also has been required in other phase I studies of everolimus in combination with tyrosine kinase inhibitors. In a phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma, dose-limiting toxicity, including thrombocytopenia, mucositis, and vomiting, was observed in the early cohorts of patients treated with everolimus 5 mg daily with sunitinib 37.5 mg daily [13] . Treatment was tolerated only at attenuated doses with a weekly, rather than daily, schedule of everolimus. Additionally, in a phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma, escalation of both agents to full monotherapy doses was not attempted due to concerns for toxicity; everolimus 5 mg daily with sorafenib 400 mg twice daily was established as the MTD in this study [14] . It is possible that synchronous blockade of the VEGF and mTOR pathways leads to synergistic toxicity. Alternatively, it is possible that drug interaction exits, leading to accumulation of sorafenib, everolimus, or active metabolites. We did not formally assess pharmacokinetic profiles in our study. However, in the phase I study of everolimus and sunitinib, the pharmacokinetic profiles for everolimus were similar to previous reports for it as a single agent, arguing against altered metabolism of everolimus due to sunitinib [13] . Similarly, there appeared to be no interaction between everolimus and sorafenib in patients with renal cell carcinoma [14] .
The combination of everolimus with a VEGF inhibitor such as bevacizumab may represent an alternative and potentially more tolerable approach to dual inhibition of the mTOR and VEGF pathways. Interim analysis of a multicenter phase II trial of the mTOR inhibitor temsirolimus with bevacizumab suggests that this combination is relatively well tolerated with anticipated toxicity and also evidence of response in excess of what would be anticipated from single-agent therapy. Among the first 25 evaluable patients, a confirmed PR was documented for 13 patients (52 %) [15] . Additionally, the combination of everolimus and bevacizumab has been found to be well tolerated and associated with antitumor activity (overall response rate 26 %) in a phase II study of patients with low-or intermediate-grade neuroendocrine tumors [16] . The results of CALGB 80701 (NCT01229943), a randomized phase II study of everolimus versus everolimus plus bevacizumab in patients with advanced pancreatic NET, will provide valuable information regarding the relative benefit of dual inhibition of the VEGF and mTOR pathways. Additional studies in the future examining the efficacy of combining everolimus and inhibitors of the VEGF pathway are also warranted.
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